Actively Recruiting
The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis
Led by Sun Yat-sen University · Updated on 2023-04-18
10
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating minocycline for chronic autoimmune uveitis, a serious non-infectious eye disease that can cause blindness due to ongoing inflammation and damage to eye structures. Current treatments like glucocorticoids, immunosuppressants, and biologics have limited success in managing this persistent condition. This trial aims to assess the effectiveness and safety of minocycline, which has shown immune-modulating and anti-apoptosis properties in other neuro-inflammatory diseases. Participants in this interventional study will take a daily oral dose of 100 mg minocycline capsules. The trial focuses on monitoring changes in eye function and structure over 6 and 12 months. Key measurements include macular sensitivity, best-corrected visual acuity (BCVA), visual field, and photopic and scotopic response changes. An evaluation of macular vessels, contrast sensitivity, color vision, and quality of life will also be conducted, along with tracking ocular and non-ocular adverse events. During the study, participants will undergo regular exams to assess vision and eye health, including tests for visual acuity, visual field, and retinal responses. Quality of life questionnaires will be collected at 6 and 12 months. Safety will be monitored through adverse event reporting and clinical assessments. Overall participation may last at least one year, with evaluations at these key time points to understand minocycline's impact on chronic autoimmune uveitis and retinal degeneration.
CONDITIONS
Brief Title
Minocycline for Chronic Autoimmune Uveitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with autoimmune disease causing vision damage such as decreased BCVA or retinal structure loss
- Aged between 18 and 60 years old
- Signed informed consent and able to attend required visits
You will not qualify if you...
- Allergy to minocycline or tetracycline antibiotics
- Abnormal liver, heart, kidney, or thyroid function
- Currently using glucocorticoids, immunosuppressants, biologics, or other medications for different diseases
- Pregnant, breastfeeding, or planning pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants take minocycline capsules 100mg daily by mouth as the active treatment for chronic autoimmune uveitis.
Visits at 6 and 12 months for assessments
Trial Site Locations
Total: 1 location
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
D
Dan Liang
Y
Yuxi Chen
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here